[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nordic Society of Gynaecological Oncology - Clinical Trials Unit\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100483410","characterization-of-epithelial-ovarian-cancer-patients-in-terms-of-homologous-recombination-phenotype-100483410",false,"NCT05574673","Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype","Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study","HERO","Patients are eligible to be included in the study, if all the following inclusion criteria are met:\n\n* Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:\n\n  * FIGO stage I-II with a known BRCA1\u002F2 mutation (germline\u002FgBRCA or somatic\u002FtBRCA)\n  * FIGO stage III-IV of any histology\n* Women aged ≥18 years of age at the time of diagnosis\n* Patients intended for platinum-based chemotherapy treatment\n* Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\n* Patients consent to provide archival tumor tissue sample\n\nPatients are ineligible to be included in the study, if any of the exclusion criteria are met:\n\n* Non-epithelial ovarian cancer, borderline tumors, or mucinous histology\n* Patients with FIGO stage I-II, BRCAwt ovarian cancer","FEMALE","18 Years","100 Years",{"count":21,"type":22},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1\u002F2 and HRD status.",[27,28,29],"Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer",[31],"Ovarian cancer, observational study, HRD","RECRUITING","2026-02-24",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2022-12-01",{"date":40,"type":22},"2032-07-01",{"name":42,"class":43},"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":24,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100450181","palliation-in-gynae-oncology-patients-expectations-and-assessment-of-care-peace-100450181","NCT05142150","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care","PEACE","Inclusion Criteria:\n\nA patient will be eligible for inclusion only if all of the following criteria are fulfilled:\n\n1. Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician\\*. Potential patient groups include, but are not limited to, those with platinum-resistant\u002Frefractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic\u002Frecurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade\u002Fundifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.\n2. Patients may be on active cancer treatment, about to commence active cancer treatment or under observation\u002Fpalliative care.\n3. Age ≥ 18 years\n4. Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol.\n2. A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.\n3. Participation in another clinical trial.\n\nA patient will be asked to appoint a carer.\n\nInclusion criteria carer:\n\n1. Age ≥ 18 years\n2. A relative or close friend who is actively supporting the patient in her illness\n3. Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion criteria carer\n\nA carer will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol\n2. A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.",{"count":54,"type":22},73,"6 Weeks","The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.",[58],"Gynaecological Cancer","2024-09-27",{"date":61,"type":36},"2024-10-01",{"date":63,"type":36},"2023-01-12",{"date":65,"type":22},"2027-12-31",{"name":42,"class":43},""]